Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Adds Two More PhRMA Lobbyists To D.C. Office

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen’s lobbying team will include PhRMA’s point person on FDA legislation (Mara Guarducci) and Medicare/reimbursement specialist (Scott Olsen). Both will report to Amgen’s newly named VP-Government Affairs Rodger Currie.

You may also be interested in...



Amgen D.C. Office Adds Two More PhRMA Lobbyists

Helen Rhee and Thomas Moore join former colleagues Currie, Guarducci and Olsen at Amgen.

Amgen D.C. Office Adds Two More PhRMA Lobbyists

Helen Rhee and Thomas Moore join former colleagues Currie, Guarducci and Olsen at Amgen.

PhRMA Makes It Official: Rep. Tauzin Takes Over As CEO Jan. 3

Chief of Staff Simoneaux and Communications Director Johnson are expected to move with Tauzin to PhRMA. The Louisiana Republican's battle with intestinal cancer will allow him to discuss his personal stake in the future of the industry as its top spokesman.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel